The effects of spiromesifen on life history traits and population growth of two-spotted spider mite (Acari: Tetranychidae)

Laboratory bioassays were conducted to evaluate the effects of spiromesifen on gross fecundity, gross fertility, net fertility and population growth of two-spotted spider mite (Tetranychus urticae Koch) after treatments with four acaricide concentrations: 180 mg/l, i.e. maximum recommended concentration for use in glasshouses against spider mites, 18, 1.8, and 0.18 mg/l, i.e. concentration discriminative for eggs and immatures in preliminary studies which produced 100% mortality of these stages. Quiescent female deutonymphs were treated in the first assay, and young pre-ovipositing females in the second and third, in which exposure lasted 6 h and 20 h, respectively. In the first assay, the 180, 18, and 1.8 mg/l concentrations significantly reduced gross fecundity (61–85%), gross fertility (64–87%) and net fertility (85–94%) of the surviving females. In the second one, only the highest concentration achieved a significant statistical reduction in gross fecundity (52%), gross fertility (67%) and net fertility (84%). In the third assay, fecundity and fertility reduction under the two highest concentrations was 98–99% and 93–98%, whereas it was 50–74% under the 1.8 mg/l concentration, and statistically different from control values. In all three trials, treatments with 180, 18, and 1.8 mg/l concentrations significantly reduced the instantaneous rate of increase. In the third assay, treatments with the two highest concentrations caused population decline. Sublethal activity of the 0.18 mg/l concentration was not found in any assay to be statistically significant. Sublethal effects of spiromesifen and its impact on T. urticae management are discussed.